Saturday 17 October 2026
Export VRCA’s income statement to Excel — free account
Verrica Pharmaceuticals Inc.
VRCA Healthcare Biotechnology
Verrica Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.6 million, up 370.2% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3,200.0%, free cash flow grew 7.63% and total debt fell 97.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.54
0.24
−6.35%
Follow VRCA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.33 | 2.49 | 3.03 | 4.30 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
4.22 | (19.28) | (12.30) | (14.05) | |
P/B ratio |
0.00 | 3.58 | 7.02 | 30.27 | |
Price to Tangible BV |
0.00 | 3.58 | 7.02 | 30.27 | |
EV/Sales |
1.77 | 2.01 | 2.83 | 4.37 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.87) | (4.05) | (7.45) | (9.92) | |
EV/FCF |
(1.86) | (4.00) | (7.32) | (9.74) | |
Quick Ratio |
0.98 | 2.16 | 1.75 | 0.99 | |
Current Ratio |
1.25 | 2.59 | 2.10 | 1.45 | |
Net Debt/EBITDA |
7.51 | 4.21 | 2.11 | 0.81 | |
Debt/Assets |
84.86% | 1.36% | 1.41% | 2.20% | |
Debt/Equity |
(2.04) | 0.03 | 0.03 | 0.18 | |
Asset Turnover |
0.84 | 0.70 | 0.92 | 0.81 | |
Operating CF/Net income |
(35.35) | 0.57 | 0.95 | 0.71 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.78 | (5.47) | (60.72) | (79.86) | |
Research and Development Expense of Revenue |
15.37% | 49.49% | 76.85% | 102.93% | |
Selling, General and Administrative Expense of Revenue |
65.55% | 159.41% | 198.87% | 176.54% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.01% | 13.47% | 17.86% | 20.69% | |
Graham Net Nets |
(0.53) | 0.23 | 0.10 | 0.01 | |
Graham Number |
11.74 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(79.12%) | (19.01%) | (19.47%) | (27.29%) | |
Free Cash Flow Yield |
(71.75%) | (20.19%) | (12.74%) | (10.43%) | |
Revenue per Share |
1.51 | 0.48 | 0.24 | 0.28 | |
Operating CF per Share |
1.02 | (0.43) | (0.43) | (0.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
1.02 | (0.43) | (0.43) | (0.44) | |
Cash per Share |
2.22 | 2.83 | 0.97 | 0.53 | |
Shareholders Equity per Share |
(1.80) | 2.32 | 0.75 | 0.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.80) | 2.32 | 0.75 | 0.20 | |
Free Cash Flow |
9.69 | (4.59) | (9.16) | (9.28) | |
Working Capital |
7.37 | 26.10 | 17.91 | 10.20 | |
Net Current Asset Value |
(21.66) | 20.15 | 11.40 | 0.93 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.71 | 2.74 | 6.73 | 14.23 | |
Average Payables |
1.28 | 1.98 | 1.82 | 1.96 | |
Average Inventory |
2.44 | 2.35 | 2.22 | 2.62 | |
Average Assets |
36.91 | 50.63 | 40.48 | 37.56 | |
Average Common Equity |
(25.55) | 7.44 | (1.26) | (6.59) |
Columns are period end dates